Aerts J et al. Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial. ASCO 2024;Abstract 2533.
Ahn M-J et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260-72. Abstract
Anagnostou V et al. ctDNA response after pembrolizumab in non-small cell lung cancer: Phase 2 adaptive trial results. Nat Med 2023;29(10):2559-69. Abstract
Cascone T et al. Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T. ASCO 2025;Abstract LBA8010.
D’Aiello A et al. Perioperative immunotherapy for non-small cell lung cancer: Practical application of emerging data and new challenges. Clin Lung Cancer 2024;25(3):197-214. Abstract
Forde PM et al. Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816. ASCO 2025;Abstract LBA8000.
Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01. WCLC 2024;Abstract PL02.11.
Ghanem P et al. Clinical and genomic characterization of long-term responders receiving immune checkpoint blockade for metastatic non-small-cell lung cancer. Clin Lung Cancer 2024;25(2):109-18. Abstract
Ghanem P et al. Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases. RMD Open 2023;9(4). Abstract
Girard N et al. Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy (CRT) in unresectable, stage III NSCLC (urNSCLC): Final data extraction from PACIFIC-R. ELCC 2025;Abstract 190P.
Heymach JV et al. Perioperative durvalumab for resectable NSCLC (R-NSCLC): Updated outcomes from the phase 3 AEGEAN trial. WCLC 2024;Abstract OA13.03.
Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501.
Mamdani H. Bispecific antibodies in action: Engineering immunity to target thoracic malignancies. ASCO 2025 Clinical Science Symposium;Abstract.
Murray JC et al. Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer. Clin Cancer Res 2024;30(2):389-403. Abstract
Paz-Ares L et al. ABBIL1TY NSCLC-06: A global, randomized, open-label, phase III trial of acasunlimab in combination with pembrolizumab (pembro) vs docetaxel in checkpoint inhibitor (CPI)-experienced patients with PD-L1+ metastatic non-small cell lung cancer (mNSCLC). ELCC 2025;Abstract 128TiP.
Peters S et al. Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic NSCLC: Five-year overall survival outcomes from the phase 3 POSEIDON trial. J Thorac Oncol 2025;20(1):76-93. Abstract
Reck M et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer 2024;211:114296. Abstract
Skoulidis F et al. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 2024;635(8038):462-71. Abstract
Spicer JD et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024;404(10459):1240-52. Abstract
Spigel DR et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022;40(12):1301-11. Abstract
Wakelee HA et al. KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. ASCO 2023;Abstract LBA1000.
Xiong A et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): A randomised, double-blind, phase 3 study in China. Lancet 2025;405(10481):839-49. Abstract
Zhou C et al. Phase 3 study of ivonescimab (AK112) vs. pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC: Primary analysis of HARMONi-2. WCLC 2024;Abstract PL02.04.